Literature DB >> 16531519

Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?

B E Sands1.   

Abstract

Immunosuppressive drugs have become a mainstay of therapy for the inflammatory bowel diseases. Although robust evidence exists in support of the use of these drugs in Crohn's disease, a close evaluation of the available data in ulcerative colitis reveals a much weaker evidence base. In particular, randomised controlled trials of azathioprine, the most commonly used immunosuppressive agent, do not provide rich evidence of efficacy whereas observational cohorts suggest this agent is effective, particularly in patients with relapsing disease who require corticosteroids. Ciclosporin is also effective in the most refractory cases but its efficacy needs to be carefully weighed against the possibility of rare but life threatening complications. Although the evidence base in support of immunosuppressive drugs in ulcerative colitis is not as strong as in Crohn's disease, these agents clearly have a role in the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16531519      PMCID: PMC1856175          DOI: 10.1136/gut.2005.078055

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  33 in total

1.  Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial.

Authors:  A Sood; V Midha; N Sood; V Kaushal
Journal:  Indian J Gastroenterol       Date:  2000 Jan-Mar

2.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.

Authors:  W A Faubion; E V Loftus; W S Harmsen; A R Zinsmeister; W J Sandborn
Journal:  Gastroenterology       Date:  2001-08       Impact factor: 22.682

3.  The treatment of chronic ulcerative colitis with 6-mercaptopurine.

Authors:  R H BEAN
Journal:  Med J Aust       Date:  1962-10-13       Impact factor: 7.738

4.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

5.  The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.

Authors:  A G Fraser; T R Orchard; D P Jewell
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

6.  Intravenous cyclosporin in ulcerative colitis: a five-year experience.

Authors:  R D Cohen; R Stein; S B Hanauer
Journal:  Am J Gastroenterol       Date:  1999-06       Impact factor: 10.864

7.  The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis.

Authors:  Ajit Sood; Vikas Kaushal; Vandana Midha; Krishan Lal Bhatia; Neena Sood; Vineeta Malhotra
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

8.  Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis.

Authors:  S Ardizzone; G Maconi; A Russo; V Imbesi; E Colombo; G Bianchi Porro
Journal:  Gut       Date:  2005-06-21       Impact factor: 23.059

9.  Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study.

Authors:  T Orth; M Peters; J F Schlaak; F Krummenauer; R Wanitschke; W J Mayet; P R Galle; M F Neurath
Journal:  Am J Gastroenterol       Date:  2000-05       Impact factor: 10.864

10.  Oral methotrexate in ulcerative colitis.

Authors:  J R F Cummings; K R Herrlinger; S P L Travis; D A Gorard; A S McIntyre; D P Jewell
Journal:  Aliment Pharmacol Ther       Date:  2005-02-15       Impact factor: 8.171

View more
  5 in total

1.  Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis.

Authors:  Taku Kobayashi; Makoto Naganuma; Susumu Okamoto; Tadakazu Hisamatsu; Nagamu Inoue; Hitoshi Ichikawa; Tetsuro Takayama; Riko Saito; Tomohisa Sujino; Haruhiko Ogata; Yasushi Iwao; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2010-07-08       Impact factor: 7.527

Review 2.  The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease.

Authors:  Makoto Naganuma; Toshimitsu Fujii; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2010-12-04       Impact factor: 7.527

3.  Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies.

Authors:  Fernando Bermejo; Javier P Gisbert
Journal:  Ther Adv Chronic Dis       Date:  2010-05       Impact factor: 5.091

Review 4.  Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-05-12       Impact factor: 4.481

5.  Cerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis.

Authors:  Gudrun Scheving Thorsteinsson; Maria Magnussson; Lena M Hallberg; Nils Gunnar Wahlgren; Fredrik Lindgren; Petter Malmborg; Thomas H Casswall
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.